Efficacy of 5-FU or Oxaliplatin Monotherapy over Combination Therapy in Colorectal Cancer

• 作者: Ioannis Papasotiriou Maria Toloudi Panagiotis Apostolou
• 来源期刊: 癌症治疗(英文)
• 学科: 医学
• 关键词: 5-FLUOROURACIL OXALIPLATIN FOLFOX COLON Cancer Stem Cells
• 年，卷（期）: azzlyw_2015,（4）
• 页码范围: 345-355
• 页数: 11页
• 分类号: R73

摘要

Recent clinical and research development supports the use of 5-fluorouracil in combination with oxaliplatin for the treatment of patients with advanced colorectal cancer (CRC). 5-Fluorouracil (5-FU), which is as an anti-metabolite, is a widely used cytostatic drug. Although the rate of response, quality of life and overall survival differs between CRC patients, the above combination remains a widely used chemotherapeutic regimen. In some cases, a cancer stem cell (CSC) population may resist the majority of chemotherapeutic models. This study investigated if monotherapy is more efficacious than 5-fluorouracil and oxaliplatin combined for the treatment of CRC, using a CRC cell line and a CSC-like line. Cell viability was evaluated by cellular-based assays, and quantitative polymerase chain reaction (q-PCR) assays were performed to assess the expression of specific genes (TYMS,?DNMT1,?NANOG, DHFR, SHMT1, ERCC1, DPYD) correlated with 5-FU and oxaliplatin resistance. We observed that 5-fluorouracil was more effective in both CRC and CSCs. This finding proved the hypothesis that, in some cases, monotherapy may be more successful in CRC treatment than a drug combination that may be cytotoxic and inflict adverse side effects.